Want to see CAMP full AI Analyst Report?

CAMP4 Therapeutics Corporation (CAMP) Price & Analysis

138 Followers

CAMP Stock Chart & Stats

$4.20

$0.15(4.98%)

At close: Jul 24 4:00 PM EDT

$4.20

$0.15(4.98%)

Day’s Range― - ―

52-Week Range$2.90 - $7.75

Previous Close$4.45

Volume169.64K

Average Volume (3M)267.63K

Market Cap

$198.30M

Enterprise Value$168.40M

Total Cash (Recent Filing)$87.13M

Total Debt (Recent Filing)$2.37M

Price to Earnings (P/E)―

Beta2.03

Next Earnings

Nov 19, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.23

Shares Outstanding62,753,200

10 Day Avg. Volume221,671

30 Day Avg. Volume267,627

Financial Highlights & Ratios

PEG Ratio6.15

Price to Book (P/B)3.90

Price to Sales (P/S)53.24

P/FCF Ratio-6.24

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue39.94

Enterprise Value/Gross Profit51.34

Enterprise Value/Ebitda-2.32

Forecast

1Y Price Target

$8.80

Price Target Upside109.52% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.14

Revenue Forecast (FY)$6.74M

Bulls Say, Bears Say

Bulls Say

Revenue And Gross Margin ImprovementImproving revenue and gross margin indicate early commercial traction and better economics in the underlying business. If sustained, these trends can increase the value of future product opportunities and provide a stronger foundation for operating leverage as clinical programs advance.

Low Absolute DebtLow absolute debt limits fixed financial obligations and reduces the immediate burden of interest and refinancing compared with a highly leveraged biotechnology company. This provides some balance-sheet flexibility, although it does not offset the company’s negative equity and ongoing cash needs.

Clinical And Pipeline ProgressRegulatory clearance and a broader genetically defined neurology pipeline show progress from discovery toward clinical development. Advancement in underserved rare disorders could expand future opportunities and create multiple sources of long-term value beyond the lead CMP-002 program.

Bears Say

Large Operating And Net LossesThe scale of operating and net losses shows that current activities are not yet commercially self-sustaining. Continued heavy investment may be necessary before meaningful profitability, leaving results highly dependent on successful development and eventual commercialization of pipeline therapies.

Persistent Cash BurnPersistent negative operating and free cash flow means the company is consuming capital rather than funding development internally. This raises the importance of external financing over the next several quarters and can constrain strategic flexibility if funding conditions or clinical requirements change.

Negative Equity And Long Clinical TimelineNegative equity signals weakened capital structure resilience, while the planned multi-year path to topline clinical data delays a potentially important value inflection. The combination leaves the company exposed to prolonged execution demands before efficacy evidence can materially reduce development uncertainty.

CAMP4 Therapeutics Corporation News

Camp4 Therapeutics initiated with a Buy at Needham

Needham initiated coverage of Camp4 Therapeutics (CAMP) with a Buy rating and $8 price target The company’s lead...

7d ago

CAMP

Camp4 Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $15 price target. The firm believes...

17d ago

CAMP

STOK

Camp4 Therapeutics price target lowered to $6 from $6.50 at Chardan

Chardan analyst Keay Nakae lowered the firm’s price target on Camp4 Therapeutics (CAMP) to $6 from $6.50 and...

23d ago

CAMP

Buy Rating Reaffirmed on CAMP4 as ASCEND Trial Strategy and Pipeline Catalysts Support Long-Term Value; Price Target Maintained at $8

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on CAMP4 Therapeutics Corporation, with...

23d ago

CAMP

CAMP4 Details ASCEND Trial Plans in SYNGAP1 Disorder

CAMP4 Therapeutics Corporation ( ($CAMP) ) has shared an update. On September 28, 2026, CAMP4 Therapeutics held an...

24d ago

CAMP

Camp4 Therapeutics reports Q2 EPS (58c), consensus (21c)

Reports Q2 revenue $1.78M, consensus $1.89M. “Having secured regulatory clearance in both Australia and Argentina, we are now...

2M ago

CAMP

Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler

Piper Sandler raised the firm’s price target on Camp4 Therapeutics (CAMP) to $15 from $12 and keeps an...

2M ago

CAMP

CAMP4 Analyst Day, Strong Cash Runway and SYNGAP1 Trial Progress Drive Upward Price-Target Revision to $8 with Buy Rating

Analyst Yun Zhong from Wedbush assigned a Buy rating on CAMP4 Therapeutics Corporation and increased the price target...

2M ago

CAMP

CAMP Upcoming Earnings Report: What to Expect?

CAMP4 Therapeutics Corporation (CAMP) is scheduled to report 2nd quarter earnings on 08/13/2026. Regarding Q2 estimates, Wall Street...

2M ago

CAMP

CAMP4 Therapeutics Secures $50 Million Private Financing

CAMP4 Therapeutics Corporation ( ($CAMP) ) has issued an update. On August 3, 2026, CAMP4 Therapeutics completed the...

3M ago

CAMP

CAMP4 gains Australian clearance, enabling CMP-002 trial and financing

CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an update. On July 27, 2026, CAMP4 Therapeutics announced it...

3M ago

CAMP

Camp4 Therapeutics receives Australia TGA clearance for CMP-002 trial

CAMP4 Therapeutics (CAMP) announced that it has received clearance from Australia’s Therapeutic Goods Administration, or TGA, and local...

3M ago

CAMP

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

X4 Pharmaceuticals (XFOR) announced the appointment of Kelly Gold to the company’s board of directors effective July 1,...

4M ago

CAMP

XFOR

Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Camp4 Therapeutics (CAMP) to Overweight from Neutral with a price target of $9, up from $5....

4M ago

CAMP

CAMP FAQ

What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?

CAMP4 Therapeutics Corporation lowest stock price was $2.90 and its highest was $7.75 in the past 12 months.

What is CAMP4 Therapeutics Corporation’s market cap?

CAMP4 Therapeutics Corporation’s market cap is $198.30M.

When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?

CAMP4 Therapeutics Corporation’s upcoming earnings report date is Nov 19, 2026 which is in 28 days.

How were CAMP4 Therapeutics Corporation’s earnings last quarter?

CAMP4 Therapeutics Corporation released its earnings results on Aug 14, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.211 by -$0.369.

Is CAMP4 Therapeutics Corporation overvalued?

According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CAMP4 Therapeutics Corporation pay dividends?

CAMP4 Therapeutics Corporation does not currently pay dividends.

What is CAMP4 Therapeutics Corporation’s EPS estimate?

CAMP4 Therapeutics Corporation’s EPS estimate is -0.19.

How many shares outstanding does CAMP4 Therapeutics Corporation have?

CAMP4 Therapeutics Corporation has 62,753,200 shares outstanding.

What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?

CAMP4 Therapeutics Corporation reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.211. Following the earnings report the stock price went up 20.889%.

Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?

Currently, no hedge funds are holding shares in CAMP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CAMP4 Therapeutics Corporation Stock Smart Score

Neutral

Fundamentals

Return on Equity

-314.08%

Trailing 12-Months

Asset Growth

82.21%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

CAMP4 Therapeutics Corporation (CAMP) Earnings & Revenues

Historic Earnings Reports

CAMP Stock 12 Month Forecast

Average Price Target

$8.80

▲(109.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","4.75":"$4.75","8.5":"$8.5","12.25":"$12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.75,8.5,12.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.6984615384615385,5.556923076923077,6.415384615384616,7.273846153846154,8.132307692307691,8.990769230769232,9.849230769230768,10.707692307692309,11.566153846153846,12.424615384615384,13.283076923076923,14.141538461538461,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.2215384615384615,4.603076923076923,4.984615384615385,5.366153846153846,5.747692307692308,6.1292307692307695,6.510769230769231,6.892307692307693,7.273846153846154,7.655384615384616,8.036923076923078,8.418461538461539,{"y":8.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.006153846153846,4.172307692307692,4.338461538461538,4.504615384615384,4.67076923076923,4.836923076923076,5.003076923076923,5.169230769230769,5.335384615384616,5.501538461538461,5.667692307692308,5.833846153846154,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.415,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >